RxDoctor Payments Data

Benjamin Vanraalte

Davenport, IANPI 1528048451

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AbbVie at 35.2% of the total.

$1,274in general payments, 2019–2025

Across 57 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$448
  • Mentor Worldwide LLC$338
  • Revance Therapeutics, Inc.$203
  • Tepha Inc$170
  • Galderma Laboratories, L.p.$71
  • Sientra, Inc.$37
  • plus $9 from 1 others
$805,062in research payments, 2019–2025

Across 25 payments — averaging $32,202 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medical Device Business Services, Inc.$525K
  • Mentor Worldwide LLC$280K
  • AbbVie$350
  • Sientra, Inc.$250

What the payments were for

  • Food & beverage$1,274100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →